- Trials with a EudraCT protocol (307)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
307 result(s) found for: Origin of life.
Displaying page 1 of 16.
EudraCT Number: 2012-001099-13 | Sponsor Protocol Number: CRAD001K24133E1 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors | |||||||||||||
Medical condition: advanced neuroendocrine tumors of gastrointestinal or lung origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001840-83 | Sponsor Protocol Number: SAGA | Start Date*: 2022-04-26 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Short-course aminoglycosides as adjunctive treatment in adults with sepsis | ||
Medical condition: Patients admitted with sepsis of unknown origin, suspected urinary origin or suspected abdominal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023032-17 | Sponsor Protocol Number: CRAD001K24133 | Start Date*: 2011-04-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors | ||
Medical condition: The study will evaluate the safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal, lung or pancreatic origin. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) SE (Prematurely Ended) GR (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020787-37 | Sponsor Protocol Number: 8159 | Start Date*: 2013-01-28 |
Sponsor Name:Universitair Medisch Centrum Groningen | ||
Full Title: Neo-adjuvant chemotherapy, cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis of colorectal origin (NACHO-trial) | ||
Medical condition: peritoneal carcinomatosis of colorectal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022025-15 | Sponsor Protocol Number: 10-2-055 | Start Date*: 2011-02-21 |
Sponsor Name:MUMC | ||
Full Title: Intradiscal Methylene Blue Injection Treatment for Chronic Discogenic Low back pain A prospective Clinical Series followed by a Randomised Placebo-Controlled Clinical Trial | ||
Medical condition: The Randomized Clinical Trial (RCT) aims to prove the hypothesis that Intradiscal Methylene blue Injection is capable of better pain reduction than the best available treatment in patients sufferin... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002134-14 | Sponsor Protocol Number: 1.0 | Start Date*: 2022-09-02 |
Sponsor Name:Catharina Hospital Eindhoven | ||
Full Title: Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study | ||
Medical condition: Patients with peritoneal carcinomatosis of colorectal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003898-86 | Sponsor Protocol Number: HL BOR 001 | Start Date*: 2005-03-07 | |||||||||||
Sponsor Name:Institut jules Bordet | |||||||||||||
Full Title: EVALUATION OF THE TREATMENT OF PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN THROUGH COMPLETE RESECTION AND HYPERTHERMIC INTRA-PERITONEAL PEROPERATIVE CHEMOTHERAPY (HIPEC) WITH OXALIPLATIN | |||||||||||||
Medical condition: Peritoneal carcinomatosis secondary to a carcinoma of colorectal or appendicular origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006056-37 | Sponsor Protocol Number: 1160.143 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:Hamilton Health Sciences Corporation | |||||||||||||
Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi... | |||||||||||||
Medical condition: MINS (myocardial injury after noncardiac surgery) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002522-36 | Sponsor Protocol Number: CPDR001E2201 | Start Date*: 2016-12-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin... | |||||||||||||
Medical condition: Advanced neuroendocrine tumor (NET) of pancreatic, GI lung origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004735-39 | Sponsor Protocol Number: M14NEC | Start Date*: 2015-11-10 |
Sponsor Name:NKI-AVL | ||
Full Title: Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin | ||
Medical condition: Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003658-13 | Sponsor Protocol Number: EWING2008 | Start Date*: 2009-03-19 | ||||||||||||||||||||||||||
Sponsor Name:Universitaetsklinikum Muenster | ||||||||||||||||||||||||||||
Full Title: EWING 2008 | ||||||||||||||||||||||||||||
Medical condition: Ewing sarcoma Malignant peripheral neuroectodermal tumour Askin tumour Atypical Ewing sarcoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) BE (Completed) NL (Completed) SE (Completed) HU (Completed) FI (Completed) LT (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001897-13 | Sponsor Protocol Number: ITM-LET-01 | Start Date*: 2017-08-22 | |||||||||||
Sponsor Name:ITM Solucin GmbH | |||||||||||||
Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar... | |||||||||||||
Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002288-24 | Sponsor Protocol Number: Ci-FCP001 | Start Date*: 2021-08-10 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Effect of citalopram on chest pain in patients with functional chest pain | ||
Medical condition: Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004664-23 | Sponsor Protocol Number: ST 200 DS 05-01 | Start Date*: 2006-05-25 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: The role of Acetyl-L-Carnitine in Reflex Sympathetic Dystrophy RDS and in Complex Regional Pain Syndrome CRPS .Pilot clinical trial. | |||||||||||||
Medical condition: Reflex Sympathetic Dystrophy RDS and Complex Regional Pain Syndrome CRPS . | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001417-36 | Sponsor Protocol Number: BluePIPAC | Start Date*: 2021-08-02 | |||||||||||
Sponsor Name:HOSPITAL CLINICO UNIVERSITARIO | |||||||||||||
Full Title: CLINICAL TRIAL PHASE IIB ON THE TREATMENT WITH PIPAC (PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY) IN PATIENTS WITH NON-RESECTABLE PERITONEAL CARCINOMATOSIS | |||||||||||||
Medical condition: Patient presenting unresectable peritoneal metastases from digestive system, ovary or primary peritoneal origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001960-31 | Sponsor Protocol Number: S54348 | Start Date*: 2013-05-03 |
Sponsor Name:UZ Leuven | ||
Full Title: Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study | ||
Medical condition: Investigation of the ischemia-reperfusion injury in patients who will undergo a liver transplantation after receiving a drug combination/multifactorial modulation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-006147-25 | Sponsor Protocol Number: UTEROXINE | Start Date*: 2022-11-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Centre de Recherche en Santé de la Femme | |||||||||||||||||||||||||||||||||
Full Title: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin (severe dysmenorrhea and/or deep dyspareunia). Phase III, single-center, randomized study vs. control group | |||||||||||||||||||||||||||||||||
Medical condition: PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001472-12 | Sponsor Protocol Number: A7501009 Amendment 1 | Start Date*: 2006-04-12 | |||||||||||
Sponsor Name:N V Organon | |||||||||||||
Full Title: A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalp... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003927-11 | Sponsor Protocol Number: A7501008 | Start Date*: 2005-08-04 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003700-10 | Sponsor Protocol Number: CL3-18886-012 | Start Date*: 2006-01-27 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An inter... | |||||||||||||
Medical condition: Ischaemic stroke or transient ischaemic attack | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Prematurely Ended) FI (Completed) ES (Completed) GB (Completed) SE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) SK (Completed) DE (Completed) IE (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
